Baader Bank Aktiengesellschaft trimmed its position in shares of Tilray Brands, Inc. (NASDAQ:TLRY – Free Report) by 90.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 40,712 shares of the company’s stock after selling 399,285 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Tilray Brands were worth $365,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. State of New Jersey Common Pension Fund D bought a new position in shares of Tilray Brands during the fourth quarter valued at about $346,000. Westend Capital Management LLC bought a new position in shares of Tilray Brands during the fourth quarter valued at about $736,000. Tudor Investment Corp ET AL bought a new position in shares of Tilray Brands during the third quarter valued at about $518,000. Swiss Life Asset Management Ltd raised its stake in shares of Tilray Brands by 222.9% during the third quarter. Swiss Life Asset Management Ltd now owns 42,503 shares of the company’s stock valued at $74,000 after acquiring an additional 29,339 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Tilray Brands by 99,204,800.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 992,049 shares of the company’s stock valued at $1,716,000 after acquiring an additional 992,048 shares during the last quarter. 9.35% of the stock is owned by institutional investors.
Tilray Brands Trading Down 3.3%
NASDAQ:TLRY opened at $5.32 on Friday. The company’s 50 day moving average price is $6.53 and its 200-day moving average price is $8.45. Tilray Brands, Inc. has a 52 week low of $3.51 and a 52 week high of $23.20. The company has a quick ratio of 1.66, a current ratio of 2.79 and a debt-to-equity ratio of 0.19. The stock has a market cap of $620.05 million, a price-to-earnings ratio of -0.39 and a beta of 1.94.
Insiders Place Their Bets
In other Tilray Brands news, Director David G. Hopkinson sold 33,556 shares of the stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.84% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have recently commented on TLRY. Canaccord Genuity Group began coverage on shares of Tilray Brands in a research note on Tuesday, January 27th. They set a “hold” rating for the company. Weiss Ratings downgraded shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. ATB Cormark Capital Markets reduced their price target on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating on the stock in a research report on Thursday, April 2nd. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Finally, Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tilray Brands currently has an average rating of “Hold” and a consensus target price of $11.50.
View Our Latest Stock Report on TLRY
Tilray Brands Company Profile
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
Featured Stories
- Five stocks we like better than Tilray Brands
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding TLRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tilray Brands, Inc. (NASDAQ:TLRY – Free Report).
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
